• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety evaluation of Fanhdi , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.

作者信息

Jimenez-Yuste Victor, Núñez Laura, Alvarez-Roman Maria Teresa, Martin-Salces Monica, Haya Saturnino, Federici Augusto B, Grifols Carlota, Mairal Esther, Torres Mireia, Páez Antonio

机构信息

Department of Hematology and Hemotherapy, Hospital Universitario La Paz, Autónoma University, Madrid, Spain.

Bioscience Research Group, Grifols, Sant Cugat del Vallès, Barcelona, Spain.

出版信息

Haemophilia. 2022 Jan;28(1):e23-e27. doi: 10.1111/hae.14453. Epub 2021 Nov 4.

DOI:10.1111/hae.14453
PMID:34735040
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10015987/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26e0/10015987/b4ed1b09380a/HAE-28-e23-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26e0/10015987/b4ed1b09380a/HAE-28-e23-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/26e0/10015987/b4ed1b09380a/HAE-28-e23-g001.jpg

相似文献

1
Efficacy and safety evaluation of Fanhdi , a plasma-derived factor VIII/ von Willebrand factor concentrate, in Von Willebrand's disease patients undergoing surgery or invasive procedures: A prospective clinical study.血浆源性凝血因子VIII/血管性血友病因子浓缩物Fanhdi在接受手术或侵入性操作的血管性血友病患者中的疗效和安全性评估：一项前瞻性临床研究。
Haemophilia. 2022 Jan;28(1):e23-e27. doi: 10.1111/hae.14453. Epub 2021 Nov 4.
2
Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.Fanhdi在血管性血友病中的疗效与安全性：前瞻性国际研究结果。
Haemophilia. 2007 Dec;13 Suppl 5:25-32. doi: 10.1111/j.1365-2516.2007.01570.x.
3
Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.VIII因子/血管性血友病因子浓缩物（海莫莱士）在预防血管性血友病患者手术或侵入性操作期间出血的疗效和安全性。
Haematologica. 2003 Nov;88(11):1279-83.
4
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.血友病和血管性血友病：2. 管理。加拿大血友病诊所主任协会
CMAJ. 1995 Jul 15;153(2):147-57.
5
Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.血友病和血管性血友病浓缩物治疗的发展与现状
Wien Klin Wochenschr. 1982 Oct 15;94(19):509-14.
6
Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.高纯度、双重病毒灭活的凝血因子VIII/血管性血友病因子浓缩物（凡迪）治疗血管性血友病的临床疗效：一项回顾性临床研究
Haemophilia. 2002 Nov;8(6):761-7. doi: 10.1046/j.1365-2516.2002.00688.x.
7
Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.血管性血友病因子/凝血因子VIII浓缩物对择期手术的血管性血友病成年和儿童患者的预防疗效及药代动力学指导剂量：来自美国和欧盟临床试验数据的汇总与对比分析
Blood Transfus. 2013 Oct;11(4):533-40. doi: 10.2450/2013.0254-12. Epub 2013 Apr 17.
8
Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.VIII 因子/von Willebrand 因子浓缩物 BIOSTATE 在 von Willebrand 病患者中的临床疗效和安全性：一项前瞻性多中心研究。
Haemophilia. 2010 Jul 1;16(4):615-24. doi: 10.1111/j.1365-2516.2010.02206.x. Epub 2010 Mar 16.
9
Clinical Efficacy and Safety of Fanhdi, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.《西班牙应用血浆源性 vWF/FVIII 浓缩物凡迪治疗血管性血友病的临床疗效和安全性：一项回顾性研究》。
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221074348. doi: 10.1177/10760296221074348.
10
Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations.患有血管性血友病及不同血管性血友病因子突变的女性的妊娠与分娩。
Haematologica. 2010 Jun;95(6):963-9. doi: 10.3324/haematol.2009.011239. Epub 2009 Nov 30.

引用本文的文献

1
Safety and Efficacy of the Use of pdVWF/FVIII-C in Patients with von Willebrand Disease: A Prospective, Observational, Post-Authorization Study.去氨加压素联合重组人凝血因子VIII治疗血管性血友病患者的安全性和有效性：一项前瞻性、观察性、上市后研究。
Clin Appl Thromb Hemost. 2025 Jan-Dec;31:10760296251327593. doi: 10.1177/10760296251327593. Epub 2025 Mar 13.
2
Recent Advances in Whiskers: Properties and Clinical Applications in Dentistry.近期胡须研究进展：特性及在牙科中的临床应用
Int J Nanomedicine. 2024 Jul 12;19:7071-7097. doi: 10.2147/IJN.S471546. eCollection 2024.
3
Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.

本文引用的文献

1
Von Willebrand's Disease.血管性血友病
N Engl J Med. 2016 Nov 24;375(21):2067-2080. doi: 10.1056/NEJMra1601561.
2
Treatment of von Willebrand disease with FVIII/VWF concentrates.使用FVIII/VWF浓缩物治疗血管性血友病
Blood Transfus. 2011 May;9 Suppl 2(Suppl 2):s9-13. doi: 10.2450/2011.003S.
3
Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
意大利血管性血友病患者中血浆源性含血管性血友病因子的凝血因子VIII浓缩物的真实世界疗效和安全性
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241264541. doi: 10.1177/10760296241264541. Epub 2024 Jul 21.
4
Knee replacement surgery in a patient with acquired von Willebrand disease: a case study with recommendations for patient management.获得性血管性血友病患者的膝关节置换手术：一项病例研究及患者管理建议
Ann Med Surg (Lond). 2024 Jan 8;86(3):1681-1686. doi: 10.1097/MS9.0000000000001690. eCollection 2024 Mar.
高纯度、双病毒灭活 VWF/FVIII 浓缩物治疗遗传性血管性血友病的疗效和安全性：意大利队列研究对 120 例根据出血严重程度评分进行特征描述的患者的研究结果。
Haemophilia. 2010 Jan;16(1):101-10. doi: 10.1111/j.1365-2516.2009.02088.x. Epub 2009 Oct 6.
4
Evidence-based recommendations on the treatment of von Willebrand disease in Italy.意大利关于血管性血友病治疗的循证推荐意见。
Blood Transfus. 2009 Apr;7(2):117-26. doi: 10.2450/2008.0052-08.
5
Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.使用Fanhdi（一种高度纯化的、双重灭活的FVIII/VWF浓缩物）治疗血管性血友病患者在出血和手术方面的临床疗效。
Haemophilia. 2008 Sep;14(5):963-7. doi: 10.1111/j.1365-2516.2008.01784.x. Epub 2008 Jul 9.
6
von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).血管性血友病（VWD）：基于证据的诊断和管理指南，美国国立心肺血液研究所（NHLBI）专家小组报告
Haemophilia. 2008 Mar;14(2):171-232. doi: 10.1111/j.1365-2516.2007.01643.x.
7
Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.Fanhdi在血管性血友病中的疗效与安全性：前瞻性国际研究结果。
Haemophilia. 2007 Dec;13 Suppl 5:25-32. doi: 10.1111/j.1365-2516.2007.01570.x.
8
Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P).使用凝血因子VIII/血管性血友病因子浓缩物（Humate-P）对接受紧急手术的血管性血友病患者进行成功治疗。
Haemophilia. 2004 Jan;10(1):42-51. doi: 10.1046/j.1351-8216.2003.00809.x.
9
Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.高纯度、双重病毒灭活的凝血因子VIII/血管性血友病因子浓缩物（凡迪）治疗血管性血友病的临床疗效：一项回顾性临床研究
Haemophilia. 2002 Nov;8(6):761-7. doi: 10.1046/j.1365-2516.2002.00688.x.
10
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.用高纯度因子VIII/血管性血友病因子浓缩物治疗血管性血友病：一项前瞻性多中心研究。
Blood. 2002 Jan 15;99(2):450-6. doi: 10.1182/blood.v99.2.450.